Trent Capital Management Inc. NC acquired a new position in ConforMIS, Inc. (NASDAQ:CFMS) during the second quarter, Holdings Channel reports. The firm acquired 31,700 shares of the medical instruments supplier’s stock, valued at approximately $136,000.

Other large investors have also made changes to their positions in the company. Spark Investment Management LLC acquired a new stake in shares of ConforMIS during the second quarter worth approximately $430,000. Goldman Sachs Group Inc. raised its stake in shares of ConforMIS by 1,313.6% in the first quarter. Goldman Sachs Group Inc. now owns 148,147 shares of the medical instruments supplier’s stock worth $773,000 after buying an additional 137,667 shares during the last quarter. Platinum Investment Management Ltd. raised its stake in shares of ConforMIS by 49.0% in the first quarter. Platinum Investment Management Ltd. now owns 271,256 shares of the medical instruments supplier’s stock worth $1,415,000 after buying an additional 89,200 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of ConforMIS by 99.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 111,500 shares of the medical instruments supplier’s stock worth $583,000 after buying an additional 55,500 shares during the last quarter. Finally, UBS Group AG raised its stake in shares of ConforMIS by 53.0% in the first quarter. UBS Group AG now owns 269,551 shares of the medical instruments supplier’s stock worth $1,407,000 after buying an additional 93,330 shares during the last quarter. Hedge funds and other institutional investors own 39.48% of the company’s stock.

Shares of ConforMIS, Inc. (NASDAQ CFMS) opened at 3.53 on Thursday. ConforMIS, Inc. has a one year low of $3.22 and a one year high of $10.93. The firm’s market capitalization is $154.79 million. The stock’s 50 day moving average price is $4.38 and its 200 day moving average price is $5.27.

ConforMIS (NASDAQ:CFMS) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.08. The company had revenue of $18.50 million during the quarter, compared to analysts’ expectations of $19.34 million. ConforMIS had a negative return on equity of 66.61% and a negative net margin of 72.87%. ConforMIS’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.34) earnings per share. Analysts expect that ConforMIS, Inc. will post ($1.30) EPS for the current fiscal year.

WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/trent-capital-management-inc-nc-acquires-shares-of-31700-conformis-inc-cfms/1467163.html.

A number of brokerages have commented on CFMS. Canaccord Genuity decreased their price objective on ConforMIS from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $6.00 price objective on ConforMIS and gave the stock a “buy” rating in a research report on Friday, August 4th. Deutsche Bank AG restated a “hold” rating and set a $5.00 price objective (down from $6.00) on shares of ConforMIS in a research report on Friday, August 4th. BTIG Research restated a “hold” rating on shares of ConforMIS in a research report on Sunday, July 16th. Finally, Zacks Investment Research upgraded ConforMIS from a “sell” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Wednesday, July 12th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $7.75.

In other news, Director Bradley Langdale sold 6,722 shares of the company’s stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $4.30, for a total transaction of $28,904.60. Following the completion of the transaction, the director now directly owns 26,533 shares of the company’s stock, valued at $114,091.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 9.55% of the stock is owned by corporate insiders.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Want to see what other hedge funds are holding CFMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ConforMIS, Inc. (NASDAQ:CFMS).

Institutional Ownership by Quarter for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.